Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury

MT Newswires Live

Feb 11, 2025

Lineage Cell Therapeutics (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.

OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.

The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.

It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.

Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.

Price: 0.64, Change: -0.02, Percent Change: -2.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510333124"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510333124\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510333124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510333124","market":"fut","top_or_hot":-1,"title":"Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.</p><p>OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.</p><p>The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.</p><p>It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.</p><p>Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.</p><p>Price: 0.64, Change: -0.02, Percent Change: -2.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-11 23:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.</p><p>OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.</p><p>The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.</p><p>It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.</p><p>Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.</p><p>Price: 0.64, Change: -0.02, Percent Change: -2.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LINE","symbol_name":"Lineage","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510333124","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510333124","pubTimestamp":1739287220,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lineage Cell Therapeutics  said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.Price: 0.64, Change: -0.02, Percent Change: -2.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LINE":"Lineage","BK4139":"生物科技","LCTX":"Lineage Cell Therapeutics Inc","LENZ":"Therapeutics","BK4224":"工业房地产信托"},"translate_title":"Lineage Cell Therapeutics开始脊髓损伤干细胞治疗试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"LINE":1,"LCTX":0.9},"content_text":"Lineage Cell Therapeutics (LCTX) said Tuesday it started a clinical study evaluating OPC1, an investigational allogeneic stem cell-derived transplant for spinal cord injury.OPC1 is designed to replace or support spinal cord cells that are absent or dysfunctional due to traumatic injury, aiming to restore or enhance functional activity in affected individuals, the company said.The company said the study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel device developed to deliver OPC1 directly to the injury site.It will enroll both subacute patients, treated between 21 and 42 days after injury, and chronic spinal cord injury patients, treated between one and five years after injury, according to the company.Shares of Lineage Cell Therapeutics were down more than 2% in recent trading.Price: 0.64, Change: -0.02, Percent Change: -2.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}